Pediatric osteosarcoma: A 35-year experience in Slovenia

Pediatric Hematology and Oncology

Volumn 22, Issue 4, 2005, Pages 335-343

  Kuhelj, Dimitrij ^a   Jereb, Berta ^b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; DOXORUBICIN; IFOSFAMIDE; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CHILD; CONVULSION; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOSARCOMA; PORTAL VEIN THROMBOSIS; RETROSPECTIVE STUDY; SLOVENIA; SURVIVAL RATE; VOMITING;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM STAGING; OSTEOSARCOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SLOVENIA; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 20044373250     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010590935257     Document Type: Article

References (24)

1. Dahlin DC, Coventry MB. Osteogenic sarcoma: a study of 600 cases. J Bone Joint Surg. 1967;49A:101-110.
2. Larsson SE, Lorentzon R, Wedren H, et al. The prognosis in osteosarcoma. Int Orthop. 1981;5:305-310.
3. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer. 1972;30:1627.
4. Bacci G, Ferrari S, Longhi A, et al. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremity: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. J Chemother. 2001;13:93-99.
5. Bielack SS, Bielack-Kempf B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group. J Clin Oncol. 2002;20:776-790.
6. Gatta G, Capocaccia R, De Angelis R, et al. Cancer survival in European adolescents and young adults. Eur J Cancer. 2003;39(18):2600-2610.
7. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of MSK (T-12) protocol. Clin Oncol. 1998;16:2452-2458.
8. Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol. 2001;12:1145-1150.
9. Enneking WF, Spanier SS, Goodman MA. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg. 1980;62-A:1027-1030.
10. Enneking WF. Musculoskeletal tumor staging: 1988 update. Cancer Treat Res. 1989;44:39-42.
11. Fukuma H, Beppu V, Yokohama R, et al. TNM classification of bone and soft tissue sarcomas. Gan To Kagaku Ryoho. 1997;24(8):1035-1040.
12. Elomaa I, Siimes M, Blomquist C, et al. Ten years experience in patients with osteosarcoma in Finland. Eur J Surg Oncol. 1990;16:147-152.
13. Kaplan EL, Meier P. Non-parametric estimation for incomplete observation. J Am Statis Assoc. 1958;53:457-481.
14. Pylkkanen L, Aho AJ, Ekfors T, et al. Treatment results of osteogenic sarcoma: an evaluation of 36 patients during 30-year period in South-Western Finland. Eur J Surg Oncol. 1997;23:54-58.
15. Sæter G, Elomaa I, Wahlqvist Y, et al. Prognostic factors in bone sarcomas. Acta Orthop Scand. 1997; (Suppl) 273:156-160.
16. Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003;39:488-494.
17. Tomer G, Cohen IJ, Kidron D, et al. Prognostic factors in non-metastatic limb osteosarcoma: a 20-year experience of one center. Int J Oncol. 1999;179-185.
18. Taylor WF, Ivins JC, Pritchard DJ, et al. Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clinic Proc. 1985;10:5-15.
19. Bielack SS, Kempf-Bielack B, Heise U, et al. Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. J Clin Oncol. 1999;17:1164.
20. Sasaki K, Jaffe N, Jaffe DM. Radiographic prognostic factors for response to chemotherapy in children and adolescents with osteosarcoma standardization of tumor size according to length of tumor, affected bone and host femur. Reg Cancer Treat 1993;1:19-25.
21. Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol. 2003;25:845-853.
22. Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol. 1997;8:765-771.
23. Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma. Cancer 1992;69:698-708.
24. Ferrari S, Briccoli A, Mercuri M, et al. Postrelaps survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol. 2003;21:710-715.